Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development
Top Cited Papers
Open Access
- 29 December 2020
- Vol. 9 (1), 71
- https://doi.org/10.3390/pr9010071
Abstract
Molecular dynamics (MD) simulations have become increasingly useful in the modern drug development process. In this review, we give a broad overview of the current application possibilities of MD in drug discovery and pharmaceutical development. Starting from the target validation step of the drug development process, we give several examples of how MD studies can give important insights into the dynamics and function of identified drug targets such as sirtuins, RAS proteins, or intrinsically disordered proteins. The role of MD in antibody design is also reviewed. In the lead discovery and lead optimization phases, MD facilitates the evaluation of the binding energetics and kinetics of the ligand-receptor interactions, therefore guiding the choice of the best candidate molecules for further development. The importance of considering the biological lipid bilayer environment in the MD simulations of membrane proteins is also discussed, using G-protein coupled receptors and ion channels as well as the drug-metabolizing cytochrome P450 enzymes as relevant examples. Lastly, we discuss the emerging role of MD simulations in facilitating the pharmaceutical formulation development of drugs and candidate drugs. Specifically, we look at how MD can be used in studying the crystalline and amorphous solids, the stability of amorphous drug or drug-polymer formulations, and drug solubility. Moreover, since nanoparticle drug formulations are of great interest in the field of drug delivery research, different applications of nano-particle simulations are also briefly summarized using multiple recent studies as examples. In the future, the role of MD simulations in facilitating the drug development process is likely to grow substantially with the increasing computer power and advancements in the development of force fields and enhanced MD methodologies.Keywords
Funding Information
- European Research Council (638965)
- VINNOVA (Dnr 2017-02690)
- Academy of Finland (315824)
This publication has 535 references indexed in Scilit:
- Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated ActivationAngewandte Chemie-International Edition, 2012
- Drug–target residence time: critical information for lead optimizationCurrent Opinion in Chemical Biology, 2010
- Cytochromes P450 in NanodiscsBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2010
- Improved side‐chain torsion potentials for the Amber ff99SB protein force fieldProteins-Structure Function and Bioinformatics, 2010
- CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fieldsJournal of Computational Chemistry, 2009
- CHARMM: The biomolecular simulation programJournal of Computational Chemistry, 2009
- Targeting cytochrome P450 enzymes: A new approach in anti-cancer drug developmentBioorganic & Medicinal Chemistry, 2007
- Comparison of multiple Amber force fields and development of improved protein backbone parametersProteins-Structure Function and Bioinformatics, 2006
- Development and testing of a general amber force fieldJournal of Computational Chemistry, 2004
- A point‐charge force field for molecular mechanics simulations of proteins based on condensed‐phase quantum mechanical calculationsJournal of Computational Chemistry, 2003